Avanir Announces U.S. Launch And Availability Of ONZETRA Xsail

(RTTNews) - Avanir Pharmaceuticals, Inc. (AVNR) announced ONZETRA Xsail or sumatriptan nasal powder is now available by prescription in U.S. pharmacies.

The U.S. Food and Drug Administration approved ONZETRA Xsail in January 2016 for the acute treatment of migraine with or without aura in adults. The approval was based on data from phase II and phase III trials, safety data from more than 300 patients and reference data from the extensive clinical use of sumatriptan over the past 20 years.

ONZETRA Xsail provides a fast-acting, 22mg dose, dry powder formulation of sumatriptan, the most commonly prescribed migraine medication, administered via the first Breath Powered intranasal medication delivery system for the acute treatment of migraine. The Xsail Breath Powered Delivery Device allows the medication to be deposited into the nose, an area that is rich with blood vessels, providing targeted and efficient delivery with the potential for fast, consistent relief, while also limiting the amount of medicine that goes down the back of the throat.